Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic characterization of DNA damage response pathway mutations reveals their adverse impact on EGFR-TKI efficacy in non-small cell lung cancer.

Respiratory research - 6 May 2026

Yang Lujie, Cheng Jinli, Guo Xin, Xiao He, Kuang Xunjie, Yang Yuxin, Zhang Lei, Zhang Qin, Wang Dong, Xu Yu, Li Mengxia

Abstract excerpt

BACKGROUND: Although tyrosine kinase inhibitors (TKIs) significantly improve survival outcomes in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), tumor clonal evolution under drug pressure inevitably leads to acquired resistance. DNA damage response (DDR) mutations lead to elevated genome instability, but the frequency and impact of DDR gene/pathway mutations on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Damage

Share to ErbB Receptors

Share to Genomics

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 42092972
DOI: 10.1186/s12931-026-03699-y
PMCID: PMC13317226

Genes

EGFR
TP53
ATM
BRCA2
MSH3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic characterization of DNA damage response pathway mutations reveals their adverse impact on EGFR-TKI efficacy in non-small cell lung cancer.PMID 42092972Read ↗

DNA damage response and repair gene mutations are associated with tumor mutational burden and outcomes to platinum-based chemotherapy/immunotherapy in advanced NSCLC patients.Semantic proximity Read ↗

Clinical significance of tumor mutation burden and DNA damage repair in advanced stage non-small cell lung cancer patients.Semantic proximity Read ↗

The enrichment of Fanconi anemia/homologous recombination pathway aberrations in ATM/ATR-mutated NSCLC was accompanied by unique molecular features and poor prognosis.Semantic proximity Read ↗

Targeting DNA Damage Response-Mediated Resistance in Non-Small Cell Lung Cancer: From Mechanistic Insights to Drug DevelopmentSemantic proximity Read ↗

DNA damage and repair (DDR) gene mutation profiles in driver gene wild-type advanced non-small cell lung cancer and the predictive role of response to platinum-based chemotherapySemantic proximity Read ↗

Comprehensive analysis of DNA damage repair deficiency in 10,284 pan-cancer studySemantic proximity Read ↗

Clinical significance of DNA damage response mutations in stage I and stage IIIa NSCLC.Semantic proximity Read ↗

DNA Damage Response and Repair Gene Alterations Increase Tumor Mutational Burden and Promote Poor Prognosis of Advanced Lung CancerSemantic proximity Read ↗

Clinical translation for targeting DNA damage repair in non-small cell lung cancer: a reviewSemantic proximity Read ↗

Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas.Semantic proximity Read ↗

Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.